Pradimicin derivatives

Abstract: The present invention relates to new antifungal compounds having the formula wherein R¹ is hydrogen, methyl, or hydroxymethyl; R² and R³ are independently selected from the group consisting of hydrogen and C₁₋₅ alkyl; and R⁴ is selected from the group consisting of β-L-xylosyl, β-D-ribosyl, α-L-arabinosyl, β-D-chinovosyl, β-D-fucosyl, and β-D-glucosyl; with the proviso that when R¹ is methyl or hydroxymethyl, and one of R² or R³ is methyl, R⁴ is not β-D-glucosyl; or a pharmaceutically acceptable salt thereof.

Description: The present invention relates to novel antifungal compounds, methods for making and using the same, and pharmaceutical compositions containing them. More particularly, the compounds of the invention are semi-synthetic pradimicin derivatives. Pradimicins, formerly called BU-3608 antibiotics, are a family of broad spectrum antibiotics active against pathogenic yeasts and fungi. A number of pradimicin compounds obtained by fermentation of Actinomadura hibisca have been reported, and their structures are shown below as formula (I): U.S. Patent No. 4,870,165 discloses pradimicins A, B, and C. Pradimicin C is identical to benanomicin B disclosed in European Patent Application No. 315,147 (published May 10, 1989). European Patent Application No. 345,735 (published December 13, 1989) discloses pradimicins D, E, and their respective desxylosyl derivatives. European Patent Application No. 351,799 (published January 24, 1990) discloses N-alkylated derivatives of pradimicins A, B, C, D, and E. European Patent Application No. 368,349 (published May 16, 1990) discloses pradimicins FA-1, FA-2, their respective desxylosyl derivatives, and N-alkylated derivatives thereof. European Patent Application No. 277,621 discloses compounds having the formula wherein R¹ is H and R² is β-D-xylosyl; or R¹ is methyl and R² is H or β-D-xylosyl. These compounds have antifungal and antiviral activities and are therefore useful for treating fungal and viral infections in animals and human beings. It will be noted that heretofore reported pradimicins possess either a monosaccharide moiety (in formula I, the amino sugar in which R c is hydrogen) or a disaccharide moiety consisting of the amino sugar and β-D-xylose linked thereto. The compounds of the present invention differ from the known pradimicins in having a sugar moiety other than D-xylosyl attached to the amino sugar. These novel compounds are also active antifungal agents. The β-D-glucosyl derivatives, disclaimed in the present application, are disclosed in the co-pending European Patent Application No. 479505 (published April 8, 1992). The present invention provides compounds having formula (II) wherein R¹ is selected from the group consisting of hydrogen, methyl, and hydroxymethyl; R² and R³ are independently hydrogen or C₁₋₅ alkyl; and R⁴ is selected from the group consisting of α-L-arabinosyl, β-D-chinovosyl (6-deoxy-β-D-glucosyl), β-D-glucosyl, and β-D-fucosyl, with the proviso that when R¹ is methyl or hydroxymethyl and one of R² or R³ is methyl, R⁴is not β-D-glucosyl; or a pharmaceutically acceptable salt thereof. The method for treating a mammalian host infected with a susceptible pathogen comprises administering to said host an antifungal effective amount of a compound of formula (II). Another aspect of the invention provides a pharmaceutical composition which comprises a compound of formula (II) and a pharmaceutically acceptable carrier. For compounds of formula (II) in which R¹ represents a methyl or a hydroxymethyl group, the resulting amino acid residue is D-alanine or D-serine, respectively. The term "alkyl" used herein encompasses straight and branched carbon chains. "Pharmaceutically acceptable salt" includes acid addition salts formed with inorganic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, and the like, or with organic acids, such as acetic acid, citric acid, fumaric acid, lactic acid, tartaric acid, and the like; base salts formed with inorganic bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate, calcium carbonate, magnesium hydroxide, and the like, or with organic bases, such as diethylamine, ethylenediamine, triethylamine, ethanolamine, and the like; and internal salt providing the zwitterion. "Desxylosylpradimicin" refers to a compound of formula (I) in which the β-D-xylosyl group has been replaced by hydrogen, and includes pradimicin B. The abbreviation "CBZ" refers to the benzyloxycarbonyl radical. A preferred embodiment of the present invention provides compounds of formula (II) wherein R¹ is methyl. Another preferred embodiment provides compounds of formula (II) wherein one of R² and R³ is hydrogen and the other is a methyl group. A more preferred embodiment provides compounds of formula (II) wherein R¹ is methyl, and one of R² and R³ is hydrogen and the other is methyl. The compounds of the present invention may be prepared by condensing an appropriately protected desxylosylpradimicin with an appropriately protected sugar under conventional glycosidation conditions. The protecting groups are then removed to afford the end products. A suitable reaction sequence is depicted below in Scheme I. In the above scheme, R 1a is hydrogen, methyl, or protected hydroxymethyl; R² is hydrogen or C₁₋₅ alkyl; P¹ is C₁₋₅ alkyl or an amino protecting group; P² and P³ are carboxyl and hydroxyl protecting groups, respectively; and n is 3 or 4. Compounds of formula (III) may be prepared from their corresponding desxylosylpradimicins, which in turn are obtained from pradimicins of formula (I) upon treatment with a mineral acid at elevated temperature for a sufficient time to allow cleavage of the xylosyl group. Thus, for example, heating pradimicin A in the presence of hydrochloric acid at 80°C for 7 hours provides pradimicin B (i.e., desxylosylpradimicin A); desxylosylpradimicins C, D, E, FA-1 and FA-2 may be prepared by similar processes. Desxylosylpradimicins C, D, and E and their preparation are disclosed in European Patent Application No. 351,799; desxylosylpradimicins FA-1 and FA-2 and their preparation are disclosed in European Patent Application No. 368,349. The disclosures of these applications are hereby incorporated by reference. The primary amino group of desxyloslypradimicins C, E and FA-2 may be converted to a secondary amine by reductive alkylation. The desxylosylpradimicin is reacted with an aldehyde or ketone having from 1 to 5 carbon atoms, preferably from 1 to 3 carbon atoms, e.g., formaldehyde, acetaldehyde, propionaldehyde, and acetone, followed by reduction of the imine thus formed. The carbonyl compound is used in about equimolar amount relative to the desxylosylpradimicin; and in order to optimize formation of the secondary amine, desxylosylpradimicin is preferably used in excess relative to the carbonyl compound. The reducing agent may be, for example, sodium borohydride, sodium cyanoborohydride, and lithium aluminum hydride. The reaction is carried out in an appropriate solvent, such as water, acetonitrile, lower alkanols, dimethyl sulfoxide, tetrahydrofuran, or a mixture thereof, at a temperature conducive to product formation, generally from about 20° to about 100°C, for a period of time sufficient to substantially complete the reaction. It will be appreciated that in the above-described reductive alkylation, a tertiary amine having two identical alkyl substituents may be obtained if the carbonyl compound is used in at least two molar equivalents relative to the desxylosylpradimicin. Desxylosylpradimicin A, D and FA-1, which have a secondary amino group, may be used as starting material to prepare tertiary amines having two methyl groups or two different alkyl substituents, one of which being a methyl group. Other tertiary amines having two different alkyl substituents may be prepared by reacting, in a similar fashion, the firstly obtained secondary amine with a second carbonyl compound different from the first one. The N-alkylation reaction described above may also be accomplished after the glycosidation reaction. The order in which the steps are performed is not particularly critical. The primary and secondary amines may be protected by acylation or formation of urethane-type derivative, e.g., with benzyl chloroformate. The free carboxyl group may be blocked by formation of esters with a lower alkanol, e.g., methanol and ethanol. In the case of desxylosylpradimicins FA-1 and FA-2, the primary hydroxyl group can be suitably protected by acylation with a carboxylic acid, e.g., acetic acid, benzoic acid, and the like. It will be appreciated that the protecting groups used are not particularly critical, and the selection of the protecting groups and methods for introducing them are well within the skills of a person skilled in the art. The compounds of formula (IV) are obtained from the corresponding 1- O -acetate sugar when treated with hydrobromic acid in acetic acid. The condensation between compounds of formulas (III) and (IV) may be carried out under standard Koenigs-Knorr conditions. Typically, a protected glycosyl halide, e.g., a peracetylated glycosyl bromide is used, and the reaction is carried out under anhydrous conditions in an inert organic solvent, such as methylene chloride, chloroform, 1,2-dichloroethane, dioxane, and the like. Anhydrous conditions may be maintained by including in the reaction mixture a dehydrating agent, such as molecular sieves. The reaction mixture also contains a silver or mercuric salt, such as mercuric cyanide or mercuric bromide. Glycosidation reaction is preferably carried out at an elevated temperature, and for a period of time, sufficient to substantially convert the starting materials into the reaction product. Generally, reaction between desxylosylpradimicin starting material (III) and the sugar at about 60°-100°C is satisfactorily complete in about 2-24 hours. The glycosidation affords the desired compound, 3'-O-coupling product of formula (V). In the case of coupling with D-glucose, two other products are also produced in addition to the expected desired product. The two coupling products have been determined to result from attachment to the 1-O- site, and their structures are shown as formulas (VI) and (VII). These side products can be separated from the desired product by chromatographic methods. The protecting groups of compounds of formula (V) are then removed to provide compounds of the present invention. The choice for deblocking method depends on the nature of the protecting groups; for example, the various ester linkages may be cleaved by hydrolysis under alkaline conditions; the benzyloxycarbonyl protecting group may be removed by catalytic hydrogenation. BIOLOGICAL ACTIVITY Antifungal activities of representative compounds of the present invention were evaluated in vitro . The minimum inhibitory concentrations (MICs) against various fungi were determined by serial agar dilution method using Sabouraud dextrose agar. Thus, approximately 0.003 ml of fungal suspension containing 10⁶ cells/ml was applied to the surface of agar plates containing the test antibiotics. The MIC values recorded after the cultures had been incubated for 40 hours at 28°C are set forth below in Table 1. For treatment of fungal infections in animals and human beings, the antibiotics of the present invention may be given in an antifungally effective amount by any accepted routes of administration; these include, but are not limited to, intravenous, intramuscular, oral, intranasal, and for superficial infections, topical administration. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, physiological saline, or some other sterile injectable medium immediately before use. Oral formulation may be in the form of tablets, gelatin capsules, powders, lozenges, syrups, and the like. For topical administration, the compound may be incorporated into lotions, ointments, gels, creams, salves, tinctures, and the like. Unit dosage forms may be prepared using methods generally known to those skilled in the art of pharmaceutical formulations. It will be appreciated that, when treating a host infected with a fungus susceptible to the antibiotics of this invention, the actual preferred route of administration and dosage used will be at the discretion of the attending clinician skilled in the treatment of fungal infections and will vary according to the causative organism, its sensitivity to the antibiotic, severity and site of the infection, and patient characteristics, such as age, body weight, rate of excretion, concurrent medications, and general physical condition. The following examples are illustrative. Preparation of 4'-N-Benzyloxycarbonylpradimicin B Methyl Ester A. Preparation of Pradimicin B A mixture of pradimicin A sodium salt (6 g, 7 mmol), acetic acid (240 ml), and 2N HCl (240 ml) was stirred at 80°C for 7 hours. The solvent was then evaporated and the residual oil dissolved in water. The solution was absorbed on µBondapak C₁₈ column (400 ml), and the column was washed with water and eluted with 25% aqueous acetonitrile (adjusted to pH 3.5 with 1N HCl). Fractions containing the desired product were collected and evaporated to give pradimicin B (3.25 g, 62% yield, purity 85% by HPLC). This product was used in the following benzyloxycarbonylation without further purifications. MP 140°C. IR (KBr) cm⁻¹: 3400, 1720, 1600. ¹H NMR (DMSO-d₆) δ: 1.27 (3H, d, J = 6.4 Hz, 5'-Me), 1.33 (3H, d, J = 7.3 Hz, 17-Me), 2.31 (3H, s, 3-Me), 2.69 (3H, s, 4'-NMe), 3.88 (1H, q, 5'-H), 4.40 (1H, dq, J 17,NH = J 17,17-Me = 7.3 Hz, 17-H), ca. 4.5-4.6 (2H, m, 5- and 6-H), 4.70 (1H, m, 1'-H), 6.96 (1H, d, J 10,12 = 2.6 Hz, 10-H), 7.18 (1H, s, 4-H), 7.31 (1H, d, 12-H), 8.08 (1H, brs, 7-H). B. Preparation of 4'-N-Benzyloxycarbonylpradimicin B A mixture of pradimicin B (3.13 g, 4.2 mmol) and N,O-bis(trimethylsilyl)acetamide (20.8 ml, 84 mmol) in dry methylene chloride (150 ml) was stirred at ambient temperature for about 0.5 hour until a solution was obtained. Benzyloxycarbonyl chloride (3.0 ml, 21 mmol) was added to the above solution, and stirring was continued for 2.5 hours. The solvent was evaporated, and to the oily residue was added methanol (210 ml) and 1N HCl (42 ml), successively, under ice-water cooling. The mixture was stirred at ambient temperature for 0.5 hour, and then the solvent was evaporated. The residue was triturated with water, filtered, and washed with water and ether, successively, to yield a solid (3.32 g, yield 94%), which consisted of 4'-N-CBZ pradimicin B (65%) and its methyl ester (19%). This sample was used for the next reaction without further purifications. A part of this sample (120 mg) was purified by C₁₈ column using 50% aqueous acetonitrile (pH 3.5 with 1N HCl) as eluent to afford 4'-N-CBZ pradimicin B (47 mg, 90% pure by HPLC). MP 215°C (dec.). IR (KBr) cm⁻¹: 3370, 1720, 1660, 1600. ¹H NMR (DMSO-d₆-D₂O) δ: 1.02 & 1.04 (3H, each d, J = 6.4 Hz, 5'-Me), 1.32 (3H, d, J = 7.3 Hz, 17-Me), 2.29 & 2.30 (3H, each s, 3-Me), 3.08 & 3.13 (3H, each s, 4'-NMe), 3.96 (3H, s, 11-OMe), 4.39 (1H, q, 17-H), 4.46 (1H, brd, J 5,6 = 10.3 Hz, 5-H), 4.54 (1H, brd, 6-H), 4.60 (1H, d, J 1',2' = 7.3 Hz, 1'-H), 5.06 & 5.10 (2H, each ABq, J = 12.8 Hz, -C H ₂Ph), 6.95 (1H, d, J 10,12 = 2.1 Hz, 10-H), 7.09 (1H, brs, 4-H), 7.30 (1H, d, 12-H), ca. 7.4 (5H, m, Ph), 8.08 (1H, brs, 7-H). FAB(+)-MS (m/z): 843 (M+H). C. Preparation of 4'-N-Benzyloxycarbonylpradimicin B Methyl Ester Thionyl chloride (1.4 ml) and 4'-N-benzyloxycarbonylpradimicin B were added to a cold mixture of methanol (100 ml) and dry 1,2-dichloroethane (30 ml), and the mixture was stirred at ambient temperature for 3 hours. The solvents were removed, and the residue was purified by silica gel (Wakogel C-200, 450 g in CHCl₃) column with CHCl₃-CH₃OH (15:1, v/v) as eluent to give 4'-N-CBZ pradimicin B methyl ester (2.80 g in 86% yield) as deep red powder, 95% pure by HPLC. MP 200°-205°C (dec.). IR (KBr) cm⁻¹: 3400, 1730, 1670, 1620, 1440. ¹H NMR (DMSO-d₆-D₂O) δ: 1.03 & 1.04 (3H, each d, J = 6.9 Hz, 5'-Me), 1.32 (3H, d, J = 7.3 Hz, 17-Me), 2.26 & 2.27 (3H, each s, 3-Me), 3.08 & 3.13 (3H, each s, 4'-NMe), 3.66 (3H, s, COOMe), 3.73 (1H, m, 5'-H), 3.93 (3H, s, 11-OMe), 4.44 (1H, q, 17-H), 4.50 (1H, d, J 5,6 = 10.9 Hz, 5-H), 4.61 (1H, d, J 1',2' = 7.6 Hz, 1'-H), [5.00 & 5.12 (1H, ABq, J = 12.9 Hz) and 5.10 (1H, s), -C H ₂Ph], 6.88 (1H, brs, 10-H), 7.04 (1H, s, 4-H), 7.25 (1H, brs, 12-H), ca. 7.4 (5H, m, Ph), 7.98 (1H, s, 7-H). FAB(+)-MS (m/z): 857 (M+H), 879 (M+Na). Example 1. Preparation of 3'-0-(β-L-xylopyranosyl)pradimicin B (Reference Example) To a suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (400 mg, 0.47 mmol) in dry 1,2-dichloroethane (40 ml) were added molecular sieves 3A (4.0 g), Hg(CN)₂ (944 mg, 3.74 mmol) and HgBr₂ (421 mg, 1.17 mmol), and the mixture was stirred at room temperature for 2 hours. To the mixture was added 2,3,4-tri-0-acetyl-L-xylopyranosyl bromide [prepared in situ from the corresponding 1-0-acetate (742 mg, 2.34 mmol) by treating with 30% HBr in acetic acid (3.7 ml) at room temperature for 2 hours and subsequent evaporation]. The mixture was stirred at 80°C overnight and then cooled to room temperature. The insoluble material was removed by filtration and washed with chloroform. The combined filtrate and washings were washed with saturated aqueous NaHCO₃ and NaCl solutions, dried over Na₂SO₄, and filtered. The filtrate obtained above (200 ml) containing 4'-N-CBZ-3'-0-(2,3,4-tri-0-acetyl-β-L-xylopyranosyl) pradimicin B methyl ester was diluted with methanol (200 ml) and then treated with 1N NaOH (20 ml). After evaporation of the solvents, the residue was dissolved in methanol (50 ml) and kept at room temperature for 2 hours. After being acidified with 1N HCl to pH 5, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The residue was chromatographed twice on C₁₈ reversed phase column by eluting with 45% aqueous acetonitrile containing 0.1% of 1N HCl. The fractions showing retention time 4.9 minutes [on HPLC; MeCN (A)/0.01M phosphate buffer (pH 3.5) (B) = 47.5/52.5] were combined and evaporated to give 4'-N-CBZ-3'-0-(β-L-xylopyranosyl) pradimicin B (53 mg, 70% pure). The N-protected derivative in MeOH (10 ml) and H₂0 (1 ml) was subjected to hydrogenolysis over Pd-C (50 mg) at room temperature for 1 hour. After removal of catalyst by filtration, the filtrate was evaporated and the residue was basified with 1N NaOH, charged on a C₁₈ column, being washed with H₂0 and then eluted with 50% aqueous MeCN. The eluate was evaporated and lyophilized to afford the title compound 22 mg (Y. 5.6%), purity 80% on HPLC [Retention time 6.2 minutes; MeCN/0.01M phosphate buffer (pH 3.5) = 35/65]. MP >230°C (dec.). IR (KBr) cm⁻¹: 3400, 1620. ¹H NMR (DMSO-d₆) δ: 1.16 (3H, d, J = 6.4 Hz, 5'-Me), 1.30 (3H, d, J = 6.8 Hz, 17-Me), 2.22 (3H, s, 3-Me), 2.39 (3H, s, 4'-NMe), 3.85 (1H, dq, 17-H), 3.87 (3H, s, 11-OMe), 4.26 (1H, d, J 1'',2'' = 7.3 Hz, 1''-H), 4.37 (1H, d, J 5,6 = 10.3 Hz, 5-H), 4.44 (1H, d, 6-H), 4.55 (1H, d, J 1',2' = 7.7 Hz, 1'-H), 6.64 (1H, br s, 10-H), 6.92 (1H, s, 4-H), 7.07 (1H, br s, 12-H), 7.37 (1H, d, J = 6.0 Hz, 16-NH), 7.69 (1H, s, 7-H). FAB(+)-MS m/z: 841 (M+H). Example 2. Preparation of 3'-O-(β-D-Ribopyranosyl)pradimicin B (Reference Example) To a suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (500 mg, 0.58 mmol) in dry 1,2-dichloroethane (50 ml) were added molecular sieves 3A (5.0 g), Hg(CN)₂ (1.18 g, 4.67 mmol), and HgBr₂ (526 mg, 1.46 mmol), and the whole mixture was stirred at room temperature for 2 hours. To the mixture obtained above was added 2,3,4-tri-O-acetyl-D-ribopyranosyl bromide, prepared in situ from its corresponding 1-O-acetate (1.11 g, 3.5 mmol) by treating with 30% HBr-AcOH (6 ml) at room temperature for 2 hours, followed by evaporation. The whole mixture was stirred at 80°C overnight. After being cooled to room temperature, the insoluble matters were removed by filtration and washed with CHCl₃. The combined filtrate and washings were washed with saturated aqueous NaHCO₃ and NaCl solutions, dried over Na₂SO₄, and filtered. The filtrate obtained above (ca. 200 ml) was diluted with MeOH (200 ml) and then treated with 1N NaOH (20 ml). After evaporation of the solvents, the residue was dissolved in MeOH (50 ml) and kept at room temperature for 2 hours. After being acidified with 1N HCl to pH 5, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The residue was chromatographed twice on C₁₈ reversed phase column by eluting with 50% aqueous acetonitrile containing 0.1% of 1N HCl. The fractions showing retention time 4.8 minutes [on HPLC; A/B = 50/50] were combined and evaporated to give the 4'-N-CBZ-3'-0-(β-D-ribopyranosyl)pradimicin B (54 mg, 80% pure). The N-protected derivative obtained above in MeOH (20 ml) and H₂O (2 ml) was subjected to hydrogenolysis over Pd-C (30 mg) at room temperature for 1 hour. After removal of the catalyst by filtration, the filtrate was evaporated and the residue was basified with 1N NaOH, charged on C₁₈ column, being washed with H₂O, and then eluted with 50% aqueous MeCN. The eluate was evaporated and lyophilized to afford the title compound 19 mg (Y. 3.9%), purity 80% on HPLC [Retention time 6.0 minutes; A/B = 30/70]. MP >230°C (dec.). IR (KBr) cm⁻¹: 3400, 1600. ¹H NMR (DMSO-d₆) δ: 1.21 (3H, d, J = 6.8 Hz, 5'-Me), 1.33 (3H, d, J = 7.3 Hz, 17-Me), 2.26 (3H, s, 3-Me), 2.56 (3H, s, 4'-NMe), 3.90 (3H, s, 11-OMe), 4.35 (1H, m, 17-H), 4.43 (1H, d, J = 10.3 Hz, 5-H), 4.48 (1H, d, 6-H), 4.68 (1H, d, J 1',2' = 7.7 Hz, 1'-H), 4.89 (1H, d, J 1'',2'' = 5.1 Hz, 1''-H), 6.71 (1H, d, J 10,12 = 2.6 Hz, 10-H), 6.88 (1H, s, 4-H), 7.12 (1H, d, 12-H), 7.67 (1H, s, 7-H), ca. 8.7 (1H, brd, NH). FAB(+)-MS m/z: 841 (M+H). Example 3. Preparation of 3'-O-(α-L-Arabinopyranosyl)pradimicin B To a suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (500 mg, 0.58 mmol) in dry 1,2-dichloroethane (50 ml) were added molecular sieves 3A (5.0 g), Hg(CN)₂ (1.18 g, 4.67 mmol), and HgBr₂ (526 mg, 1.46 mmol), and the whole mixture was stirred at room temperature for 2 hours. To the mixture obtained above was added 2,3,4-tri-O-acetyl-L-arabinopyranosyl bromide, prepared in situ from its corresponding 1-O-acetate (557 mg, 1.75 mmol) by treating with 30% HBr-AcOH (3 ml) at room temperature for 2 hours, followed by evaporation. The whole mixture was stirred at 80°C overnight. After being cooled to room temperature, the insoluble matters were removed by filtration and washed with CHCl₃. The combined filtrate and washings were washed with saturated aqueous NaHCO₃ and NaCl solutions, dried over Na₂SO₄, and filtered. The filtrate obtained above (200 ml) was diluted with MeOH (200 ml) and then treated with 1N NaOH (20 ml). After evaporation of the solvents, the residue was dissolved in MeOH (50 ml) and kept at room temperature for 2 hours. After being acidified with 1N HCl to pH 5, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The residue was chromatographed twice on C₁₈ reversed phase column by eluting with 50% aqueous acetonitrile containing 0.1% of 1N HCl. The fractions showing retention time 4.9 minutes [on HPLC; A/B = 47.5/52.5] were combined and evaporated to give 4'-N-CBZ-3'-0-(α-L-arabinopyranosyl)pradimicin B (59 mg, 80% pure). The N-protected derivative obtained above in MeOH (10 ml) and H₂O (1 ml) was subjected to hydrogenolysis under H₂ atmosphere over Pd-C (50 mg) at room temperature for 1 hour. After removal of catalyst by filtration, the filtrate was evaporated and the residue was basified with 1N NaOH, charged on C₁₈ column, being washed with H₂O and then eluted with 50% aqueous MeCN. The eluate was evaporated and lyophilized to afford the title compound 29 mg (Y. 5.9%), purity 90% on HPLC [Retention time 5.9 minutes; A/B = 30/70]. MP >230°C (dec.). IR (KBr) cm⁻¹: 3380, 1610, 1435. ¹H NMR (DMSO-d₆) δ: 1.15 (3H, d, J = 6.4 Hz, 5'-Me), 1.30 (3H, d, J = 6.8 Hz, 17-Me), 2.22 (3H, s, 3-Me), 2.42 (3H, s, 4'-NMe), 3.87 (3H, s, 11-OMe), 4.37 (1H, q, J 1'',2'' = 6.4 Hz, 1''-H), 4.37 (1H, d, J 5,6 = 11.0 Hz, 5-H), 4.45 (1H, d, 6-H), 4.58 (1H, d, J 1',2' = 7.3 Hz, 1'-H), 6.65 (1H, brs, 10-H), 6.91 (1H, s, 4-H), 7.07 (1H, brs, 12-H), 7.38 (1H, d, 16-NH), 7.69 (1H, s, 7-H). FAB(+)-MS m/z: 841 (M+H). Example 4. Preparation of 3'-O-(6-Deoxy-β-D-glucopyranosyl)pradimicin B To a suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (500 mg, 0.58 mmol) in dry 1,2-dichloroethane (50 ml) were added molecular sieves 3A (5.0 g), Hg(CN)₂ (1.18 g, 4.67 mmol), and HgBr₂ (526 mg, 1.46 mmol), and the whole mixture was stirred at room temperature for 2 hours. To the mixture obtained above was added 2,3,4-tri-O-acetyl-6-deoxy-D-glucopyranosyl bromide, prepared in situ from its corresponding 1-O-acetate (800 mg, 2.41 mmol) by treating with 30% HBr-AcOH (4 ml) at room temperature for 2 hours, followed by evaporation. The whole mixture was stirred at 80°C overnight. After being cooled to room temperature, the insoluble matters were removed by filtration and washed with CHCl₃. The combined filtrate and washings were washed with saturated aqueous NaHCO₃ and NaCl solutions, dried over Na₂SO₄, and filtered. The filtrate obtained above (ca. 200 ml) was diluted with MeOH (200 ml) and then treated with 1N NaOH (20 ml). After evaporation of the solvents, the residue was dissolved in MeOH (50 ml) and kept at room temperature for 2 hours. After being acidified with 1N HCl to pH 2, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The residue was chromatographed twice on C₁₈ reversed phase column by eluting with 50% aqueous acetonitrile containing 0.1% of 1N HCl. The fractions showing retention time 4.5 minutes [on HPLC; A/B = 50/50] were combined and evaporated to give 4'-N-CBZ-3'-0-(6-deoxy-β-D-glucopyranosyl)pradimicin B (55 mg, 80% pure). The N-protected derivative obtained above in MeOH (10 ml) and H₂O (2 ml) was subjected to hydrogenolysis over Pd-C (25 mg) at room temperature for 1 hour. After removal of catalyst by filtration, the filtrate was evaporated and the residue was basified with 1N NaOH, charged on C₁₈ column, being washed with H₂O and then eluted with 50% aqueous MeCN. The eluate was evaporated and lyophilized to afford the title compound 16 mg (Y. 3.2%), purity 80% on HPLC [Retention time 7.0 minutes; A/B = 30/70]. MP 220°C (dec.). IR (KBr) cm⁻¹: 3400, 1620, 1600. ¹H NMR (DMSO-d₆) δ: 1.17 (3Hx2, d, J = 6.0 Hz, 5'- and 5''-Me), 1.33 (3H, d, J = 6.8 Hz, 17-Me), 2.26 (3H, s, 3-Me), 2.41 (3H, s, 4'-NMe), 3.90 (3H, s, 11-OMe), 4.27 (1H, m, 17-H), 4.37 ( 1H, d, J 1'',2'' = 7.3 Hz, 1''-H), 4.39 (1H, d, J 5,6 = 10.7 Hz, 5-H), 4.44 (1H, d, 6-H), 4.60 (1H, d, J 1',2' = 7.3 Hz, 1'-H), 6.70 (1H, brs, 10-H), 6.90 (1H, s, 4-H), 7.11 (1H, brs, 12-H), 7.71 (1H, s, 7-H). FAB(+)-MS m/z: 855 (M+H). Example 5. Preparation of 3'-O-(β-D-Fucopyranosyl)pradimicin B To a suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (500 mg, 0.58 mmol) in dry 1,2-dichloroethane (50 ml) were added molecular sieves 3A (5.0 g), Hg(CN)₂ (1.18 g, 4.67 mmol), and HgBr₂ (526 mg, 1.46 mmol), and the whole mixture was stirred at room temperature for 2 hours. To the mixture obtained above was added 2,3,4-tri-O-acetyl-D-fucopyranosyl bromide, prepared in situ from its corresponding 1-O-acetate (1.16 g, 3.0 mmol) by treating with 30% HBr-AcOH (6 ml) at room temperature for 2 hours, followed by evaporation. The whole mixture was stirred at 80°C overnight. After being cooled to room temperature, the insoluble matters were removed by filtration and washed with CHCl₃. The combined filtrate and washings were washed with saturated aqueous NaHCO₃ and NaCl solutions, dried over Na₂SO₄, and filtered. The filtrate obtained above (ca. 200 ml) was diluted with MeOH (200 ml) and then treated with 1N NaOH (20 ml). After evaporation of the solvents, the residue was dissolved in MeOH (50 ml) and kept at room temperature for 2 hours. After being acidified with 1N HCl to pH 5, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The residue was chromatographed twice on C₁₈ reversed phase column by eluting with 50% aqueous acetonitrile containing 0.1% of 1N HCl. The fractions showing retention time 5.5 minutes [on HPLC; A/B = 50/50] were combined and evaporated to give 4'-N-CBZ-3'-0-(β-D-fucopyranosyl)pradimicin B (76 mg, 80% pure). The N-protected derivative obtained above in MeOH (20 ml) and H₂O (2 ml) was subjected to hydrogenolysis over Pd-C (40 mg) at room temperature for 1 hour. After removal of catalyst by filtration, the filtrate was evaporated and the residue was basified with 1N NaOH, charged on C₁₈ column, being washed with H₂O and then eluted with 50% aqueous MeCN. The eluate was evaporated and lyophilized to afford the title compound 23 mg (Y. 4.6%), purity 90% on HPLC [Retention time 7.5 minutes; A/B = 30/70]. MP 215°C (dec.). IR (KBr) cm⁻¹: 3390, 1610. ¹H NMR (DMSO-d₆-D₂O) δ: 1.13 and 1.15 (each 3H, each d, J = 6.4 and 6.8 Hz, 5'- and 5''-Me), 1.29 (3H, d, J = 6.8 Hz, 17-Me), 2.21 (3H, s, 3-Me), 2.37 (3H, s, 4'-NMe), 3.86 (1H, q, J = 6.8 Hz, 17-H), 4.29 (1H, d, J 1'',2'' = 6.8 Hz, 1''-H), 4.38 (1H, d, J 5,6 = 11.1 Hz, 5-H), 4.44 (1H, d, 6-H), 4.59 (1H, d, J 1',2' = 6.8 Hz, 1'-H), 6.68 (1H, brs, 10-H), 6.94 (1H, s, 4-H), 7.12 (1H, brs, 12-H), 7.66 (1H, s, 7-H). FAB(+)-MS m/z: 855 (M+H). Example 6. Preparation of Pradimicin L (3'-0-β-D-glucopyranosylpradimicin B) To an hour stirred suspension of 4'-N-benzyloxycarbonylpradimicin B methyl ester (1.03 g, 1.2 mmol), mercuric cyanide (2.43 g, 9.2 mmol), mercuric bromide (1.08 g, 3 mmol), and molecular sieves 3A (12 g) in dry 1,2-dichloroethane (240 ml) was added tetra-O-acetyl-α-D-glucopyranosyl bromide (1.48 g, 3 mmol), and the mixture was heated at 90°C (bath temperature) with stirring. After 15, 21, and 84 hours, a set of mercuric cyanide (2.43 g), mercuric bromide (1.08 g), and tetra-O-acetylglucosyl bromide (1.48 g) were added, and the mixture was heated for a total of 103 hours. After the insolubles were filtered and washed with chloroform, the combined filtrates were washed with 10% aqueous NaHCO₃, water and brine, dried over Na₂SO₄, and evaporated in vacuo . The residual oil (5.97 g) was chromatographed on silica gel (Wakogel C-200, 100 g in toluene) column using toluene, toluene-ethyl acetate (2:1), and chloroform-methanol (10:1) as eluents. The CHCl₃-MeOH eluents were combined and evaporated. The residue (2.70 g) was separated by a column of silica gel (Wakogel C-200, 100 g in CHCl₃), eluting with chloroform-methanol (100:1, 50:1, 25:1, and 10:1) to give 2 fractions of coupling products, Fraction A (Rf 0.35 on tlc, CHCl₃:MeOH = 25:1; deep-red powder, 283 mg) and Fraction B (Rf 0.52, orange powder, 2.03 g). To a solution of Fraction A (270 mg) in methanol (27 ml) was added 1N-NaOH (6 ml), and the mixture was stirred at ambient temperature for 1 hour. After neutralization to pH 6.5 with 1N HCl, the mixture was diluted with water (100 ml) and the organic solvent removed by evaporation. The aqueous solution was passed on a column of Diaion HP-20 (50 ml), and the column was washed with water and eluted with 40% aqueous acetonitrile to afford a crude fraction containing 4'-N-benzyloxycarbonylpradimicin L (224 mg), which was further purified by a reversed phase column (Waters, µBondapak C₁₈, 55-105µ, 400 ml), eluting with 45% aqueous acetonitrile (pH 3.5 with 1N HCl) to yield semi-pure 4'-N-CBZ-pradimicin L (57 mg), purity 75% on HPLC [Retention time 9.4 minutes; A/B = 40/60]. A mixture of 4'-N-CBZ-pradimicin L (50 mg) and 10% Pd-C (20 mg) in methanol (20 ml) and water (4 ml) was hydrogenated for 2 hours. The catalyst was removed, the filtrate was evaporated, and the residue was purified on a reversed phase column (Waters, µBondapak C₁₈, 80 ml) with 20-25% aqueous acetonitrile (pH 3.5 with 1N HCl) as eluents to give the desired pradimicin L (12 mg, yield 1.1%) as a deep-red powder. MP 155°C (dec.). IR (KBr) cm⁻¹: 1600, 1510. ¹H NMR (DMSO-d₆) δ: 1.28 (3H, d, J = 6.8 Hz, 5'-CH₃), 1.33 (3H, d, J = 7.7 Hz, 17-CH₃), 2.31 (3H, s, 3-CH₃), 2.72 (3H, brs, 4'-NCH₃), 3.96 (3H, s, 11-OCH₃), 4.40 (H, quintet, J = 7.3 Hz, 17-H), 4.48 (1H, d, J = 7.3 Hz, 1''-H), 4.61 (2H, brs, 5-H and 6-H), 4.80 (1H, brd, 1'-H), 6.96 (1H, d, J = 2.6 Hz, 10-H), 7.11 (1H, s, OH), 7.14 (1H, s, 4-H), 7.31 (1H, d, J = 2.6 Hz, 12-H), 7.36 (1H, s, OH), 8.05 (1H, s, 7-H). FAB(+)-MS m/z: 873 (M+3H). Purity 85% on HPLC [Retention time 17.4 minutes; A/B = 25/75]. Fraction B, obtained above, was subjected to alkaline hydrolysis and subsequent hydrogenation according to a procedure similar to that described for Fraction A to give two 1-O-β-D-glucosylated products, i.e., compounds of formulas (VI) and (VII), whose physical properties are provided below: Compound of Formula (VI) MP >205°C. IR (KBr) cm⁻¹: 1620, 1600. In Water: 234 (225), 284 (192), 460 (94). In 0.01N HCl: 234 (244), 285 (214), 460 (107). In 0.01N NaOH: 260 (277), 328 (sh, 81), 519 (130). ¹H NMR (DMSO-d₆/D₂O) δ: 1.29 (3H, d, J = 6.8 Hz, 5'-CH₃), 1.39 (3H, d, J = 7.3 Hz, 17-CH₃), 2.32 (3H, s, 3-CH₃), 2.75 (3H, s, 4'-NCH₃), 3.96 (3H, s, 11-OCH₃), 4.04 (1H, d, J = 7.7 Hz, 1'''-H), 4.49 (1H, d, J = 7.3 Hz, 1''-H), 4.60 (1H, d, J = 11.1 Hz, 5-H), 4.64 (1H, d, J = 11.1 Hz, 6-H), 4.86 (1H, d, J = 7.7 Hz, 1'-H), 6.93 (1H, d, J = 2.6 Hz, 10-H), 7.28 (1H, d, J = 2.6 Hz, 12-H), 7.42 (1H, s, 4-H), 8.04 (1H, s, 7-H). FAB(+)-MS m/z: 1035 (M+3H). Purity 85% (by HPLC). Compound of Formula (VII) MP >140°C (dec.). IR (KBr) cm⁻¹: 1620, 1600. In Water: 234 (280), 284 (244), 460 (122). In 0.01N HCl: 234 (244), 285 (213), 460 (106). In 0.01N NaOH: 260 (244), 328 (sh, 72), 519 (112). ¹H NMR (DMSO-d₆) δ: 1.29 (3H, d, J = 6.8 Hz, 5'-CH₃), 1.39 (3H, d, J = 7.3 Hz, 17-CH₃), 2.33 (3H, s, 3-CH₃), 2.73 (3H, s, 4'-NCH₃), 3.83 (1H, dd, J = 9.8 and 4.3 Hz, 3'-H), 3.88 (Hz, q, J = 6.8 Hz, 5'-H), 3.96 (3H, s, 11-OCH₃), 4.05 (1H, d, J = 7.7 Hz, 1'''-H), 4.44 (1H, quintet, J = 7.3 Hz, 17-H), 4.54 (1H, d, J = 11.1 Hz, 5-H), 4.62 (Hz, ddd, J = 11.1, 3.8 and 0.9 Hz, 6-H), 4.74 (1H, d, J = 7.3 1H, 1'-H), 6.30 (1H, br, 3'-OH), 6.95 (1H, d, J = 2.6 Hz, 10-H), 7.26 (1H, d, J = 2.6 Hz, 12-H), 7.43 (1H, s, 4-H), 8.04 (1H, d, J = 0.9 Hz, 7-H). FAB(+)-MS m/z: 873 (M+3H). Purity 60% (by HPLC). Example 7 The general procedure described in Examples 1-6 is repeated using the following desxylosylpradimicin and a sugar starting material selected from those described in Examples 1-6 to produce the named product of formula (II).

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE A compound having the formula wherein R¹ is hydrogen, methyl, or hydroxymethyl; R² and R³ are independently selected from the group consisting of hydrogen and C₁₋₅ alkyl; and R⁴ is selected from the group consisting of α-L-arabinosyl, β-D-chinovosyl, β-D-fucosyl, and β-D-glucosyl; with the proviso that when R¹ is methyl or hydroxymethyl, and one of R² or R³ is methyl, R⁴ is not β-D-glucosyl; or a pharmaceutically acceptable salt thereof. A compound of Claim 1 wherein R¹ is methyl. A compound of Claim 1 wherein R² is hydrogen and R³ is methyl. A compound of Claim 2 wherein R¹ is methyl, R² is hydrogen, and R³ is methyl. A compound of Claim 4 wherein R⁴ is α-L-arabinosyl. A compound of Claim 4 wherein R⁴ is β-D-chinovosyl. A compound of Claim 4 wherein R⁴ is β-D-fucosyl. A pharmaceutical composition which comprises at least one compound of any one of Claims 1 to 7 and a pharmaceutically acceptable vehicle. A process for preparing the composition of claim 8 which comprises incorporating at least one compound of any one of claims 1 to 7 into a pharmaceutically acceptable vehicle. The use of at least one compound of any one of Claims 1 to 7 for preparing a pharmaceutical composition for treating fungal infection in an animal or human host. Claims for the following Contracting State : ES A process for preparing a compound having the formula (II) wherein R¹ is hydrogen, methyl, or hydroxymethyl; R² and R³ are independently selected from the group consisting of hydrogen and C₁₋₅-alkyl; and R⁴ is selected from the group consisting of α-L-arabinosyl, β-D-chinovosyl, β-D-fucosyl, and β-D-glucosyl; with the proviso that when R¹ is methyl or hydroxymethyl, and one of R² or R³ is methyl, R⁴ is not β-D-glucosyl; or a pharmaceutically acceptable salt thereof, which comprises condensation of an appropriately protected desxylosylpradimicine of formula (III) wherein R 1a is hydrogen, methyl or protected hydroxymethyl, R² is hydrogen or C₁₋₅-alkyl, p¹ is C₁₋₅-alkyl or an amino protecting group and p² is a carboxyl protecting group with an appropriately protected glycosyl-1-halide, in particular glycosyl-1-bromide, in which the glycosyl moiety is selected from L-arabinosyl, D-chinovosyl, D-fucosyl or D-glucosyl, under glycosidation conditions, and removal of the protecting groups. A process according to Claim 1 for preparing a compound of formula II, wherein R¹ is methyl. A process according to Claim 1 for preparing a compound of formula II, wherein R² is hydrogen and R³ is methyl. A process according to Claim 2 for preparing a compound of formula II, wherein R¹ is methyl, R² is hydrogen, and R³ is methyl. A process according to Claim 4 for preparing a compound of formula II, wherein R⁴ is α-L-arabinosyl. A process according to Claim 4 for preparing a compound of formula II, wherein R⁴ is β-D-chinovosyl. A process according to Claim 4 for preparing a compound of formula II, wherein R⁴ is β-D-fucosyl. A process for preparing a pharmaceutical composition which comprises incorporating at least one compound of any one of claims 1 to 7 into a pharmaceutically acceptable vehicle. Claims for the following Contracting State : GR A compound having the formula wherein R¹ is hydrogen, methyl, or hydroxymethyl; R² and R³ are independently selected from the group consisting of hydrcgen and C₁₋₅ alkyl; and R⁴ is selected from the group consisting of α-L-arabinosyl, β-D-chinovosyl, β-D-fucosyl, and β-D-glucosyl; with the proviso that when R¹ is methyl or hydroxymethyl, and one of R² or R³ is methyl, R⁴ is not β-D-glucosyl; or a pharmaceutically acceptable salt thereof. A compound of Claim 1 wherein R¹ is methyl. A compound of Claim 1 wherein R² is hydrogen and R³ is methyl. A compound of Claim 2 wherein R¹ is methyl, R² is hydrogen, and R³ is methyl. A compound of Claim 4 wherein R⁴ is α-L-arabinosyl. A compound of Claim 4 wherein R⁴ is β-D-chinovosyl. A compound of Claim 4 wherein R⁴ is β-D-fucosyl. A process for preparing a pharmaceutical composition which comprises incorporating at least one compound of any one of claims 1 to 7 into a pharmaceutically acceptable vehicle. The use of at least one compound of any one of Claims 1 to 7 for preparing a pharmaceutical composition for treating fungal infection in an animal or human host.

Inventors: ABURAKI SHIMPEI, NAITO TAKAYUKI, YAMASHITA HARUHURO, ABURAKI, SHIMPEI, NAITO, TAKAYUKI, YAMASHITA, HARUHURO
Applicants: SQUIBB BRISTOL MYERS CO, BRISTOL-MYERS SQUIBB COMPANY
Application year: 1991
Main classification: C07H15
IPC codes: A61K31, A61P31, C07H15